Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) shot up 0.5% during trading on Tuesday . The company traded as high as $1.89 and last traded at $1.84. 126,674 shares were traded during mid-day trading, a decline of 45% from the average session volume of 229,457 shares. The stock had previously closed at $1.83.
MAIA Biotechnology Stock Down 4.0%
The firm has a market cap of $58.50 million, a price-to-earnings ratio of -2.44 and a beta of 0.03. The company's fifty day moving average is $1.82 and its 200 day moving average is $1.89.
Insider Buying and Selling
In other MAIA Biotechnology news, Director Stan Smith bought 33,333 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were acquired at an average cost of $1.50 per share, with a total value of $49,999.50. Following the acquisition, the director owned 1,305,059 shares of the company's stock, valued at $1,957,588.50. The trade was a 2.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 32.32% of the company's stock.
Institutional Trading of MAIA Biotechnology
A hedge fund recently bought a new stake in MAIA Biotechnology stock. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 39,057 shares of the company's stock, valued at approximately $77,000. Jane Street Group LLC owned approximately 0.15% of MAIA Biotechnology as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 5.65% of the company's stock.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
See Also
Before you consider MAIA Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.
While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.